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Reliable surrogate markers of response to anticancer therapy remain a desirable tool for preclinical modelling and clinical practice in
oncology. Clinical evaluation is relatively unreliable when attempting to assess rapidly and prospectively the outcome of treatment.
Fluxes in released or circulating tumour marker levels are a useful but inconsistent marker of cytotoxic response. Serial measurement
of circulating tumour cells appears to have some utility as a surrogate marker, but assay systems are expensive, and many cancers are
not associated with the presence of circulating tumour cells. Because tissue breakdown is associated with release of nucleic acids and
other cellular products, we reasoned that serial measurement of intra-tumoural pH may correlate with the extent of tumour lysis, and
thus with outcomes of cytotoxic chemotherapy. Doxorubicin-sensitive and doxorubicin-resistant sublines of P388 murine monocytic
leukaemia in C57BL/6 mice were treated with increasing concentrations of doxorubicin. Tumours were serially measured by
conventional bi-dimensional methods and pH was sampled using a bevelled tip electrode. Mean and median pH changes were
statistically different in responsive and resistant tumours, and amplitude of change correlated with long-term responses to
doxorubicin. Serial sampling of pH in tumour masses may provide a useful surrogate of long-term response to chemotherapy.
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The clinical assessment of cytotoxic response to a chemotherapy
agent or regimen is a relatively standardised process, involving the
documentation of initial extent of disease and the use of serial
measurement by clinical or radiological techniques (Husband et al,
2004). This process usually takes place during a period of several
weeks or months of chemotherapy, and the first assessment is
usually carried out after the delivery of 2–3 cycles of treatment,
usually correlating with a time lapse of 2–3 months. The
limitations of clinical assessment of tumour response have been
detailed extensively (Warr et al, 1984; Therasse et al, 2005), but
this paradigm has been the best available technique, although
patients destined not to respond may suffer unnecessary toxicities
of therapy until the emerging therapeutic failure is recognised.
More recently, serial assessment of tumour antigens (Hussain et al,
2006) and measurement of circulating tumour cells (Cristofanilli et al,
2004; de Bono et al, 2008) have been tested as surrogate markers of
response to treatment. Although in several collaborative studies, we
have shown that each approach has utility (Cristofanilli et al, 2004;
Hussain et al, 2006; de Bono et al, 2008), important limitations have
been identified: many tumours do not produce tumour-associated
antigens, or there will be discordance between fluctuations in serial
levels and response to treatment (Cristofanilli et al,2 0 0 4 ) .S i m i l a r l y ,
some tumours are not associated with the elaboration of tumour cells
in the circulation, in which case the latter assay has only a limited
function (Budd et al, 2006).
It is well known that cell death or necrosis is associated
with breakdown of cancer tissues, with the release of nucleic acids
and other intra-cellular components (Tredan et al, 2007).
In fact, tumours per se are often associated with an acidic extra-
cellular environment (Wike-Hooley et al, 1985). In highly
responsive tumours, such as lymphomas and the paediatric
malignancies, cytotoxic treatment of large volume cancer can be
associated with tumour lysis syndrome, with rapid and cata-
strophic release of large amounts of intra-cellular material into the
blood stream, culminating in acidosis and acute renal failure (Tiu
et al, 2007).
We have reasoned that, in less extreme situations, effective
chemotherapy may still be associated with less dramatic
release of breakdown products, with associated acidosis,
and that the serial measurement of extra-cellular pH within
individual tumour masses may show that the extent of
response correlates with the extent of pH reduction in
extra-cellular fluid. We propose that this could provide a simple
and reproducible early surrogate of tumour response that
might be available as a guide to treatment earlier than conven-
tional means, and that might even be a more accurate
long-term predictor of outcome. Thus we hypothesise that a
responsive tumour will undergo early tumour necrosis in
response to chemotherapy and that this will lead to local release
of nucleic acids, in turn correlating with a measurable fall in pH
within the tumour. We further hypothesise that the extent of pH
change will correlate with duration of response. We have thus
developed a preclinical model, contrasting the clones of cytotoxic-
responsive and cytotoxic-resistant cell lines, to address this
hypothesis.
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sMATERIALS AND METHODS
Cell lines
P388 murine monocytic leukaemia cells (ATCC, Manassas, VA,
USA) were maintained in RPMI-1640 (Mediatech Inc., Herndon,
VA, USA) and 5% FBS (HyClone, Logan, UT, USA). The parental
doxorubicin (adriamycin, ADR)-sensitive and the ADR-resistant
sublines of B16-BL6 mouse melanoma (selected by exposure to
increasing concentrations of ADR in vitro) were a gift from Dr
Ram Ganapathi (Cleveland Clinic, Cleveland, OH, USA). B16-BL6
cells were maintained in DMEM (Mediatech Inc.) and 5% FBS
(HyClone) without ADR. The resistant subline was adapted to
grow in the presence of 0.25mgml
 1 ADR in monolayer culture.
Resistance was confirmed in antiproliferative assays (Figure 4).
The tumourigenicity in C57BL/6 mice of the ADR-resistant subline
was similar to parental sensitive cells following subcutaneous (s.c.)
implantation of 1 million tumour cells. All cell lines were
confirmed mycoplasma free by PCR.
Reagents
Cyclophosphamide monohydrate (Sigma-Aldrich, St Louis, MO,
USA) and ADR (doxorubicin HCl; Sigma-Aldrich) were used in
these studies. Cyclophosphamide (Cy) was prepared in DMSO
(15mgml
 1) and given as a single 100mgkg
 1 intraperitoneal
(i.p.) dose on day 9 during treatment of mice bearing P388
leukaemia. Doxorubicin (2mgkg
 1 i.p.) was given daily for 6 days,
starting on day 6 after B16-BL6 tumour cell inoculation. Doses
were based on previous experience and reflected maximum
tolerated mouse doses that were associated with tumour response
with tolerable toxicity (Ganapathi et al, 1988). Control mice
received phosphate-buffered saline (PBS), consisting of monobasic
potassium phosphate (1.54mM), dibasic sodium phosphate
(2.71mM), and sodium chloride (155mM), pH 7.2.
Antiproliferative assays
Cells were treated with doxorubicin during growth in RPMI-1640
(Mediatech Inc.) and 5% FBS (HyClone). Doxorubicin was added
6h after plating cells to allow cells to adhere to the wells before
drug exposure. Growth was monitored using a colorimetric assay
(Skehan et al, 1990). Each treatment group contained eight
replicates. Cells were fixed and stained with sulphorhodamine B
after 4 days. Bound dye was eluted from cells and absorbance
(Aexp) was measured at 570nm. One plate was fixed 8h after
plating to determine the absorbance representing starting cell
number (Aini). Absorbance with this plate and that obtained with
untreated cells at the end of the growth period (Afin) were taken as
0 and 100% growth, respectively. Thus,
Percentcontrolgrowth ¼ 100% ðAexp   AiniÞ=ðAfin   AiniÞ
Expressed as a percent of untreated controls, a decrease in cell
number (relative to starting cell number) is a negative number on
the y-axis.
Measurement of pH in vivo
DBA/2 mice (n¼24 each group) were inoculated in the flank with
0.1 10
6 P388 murine monocytic leukaemia cells. Tumours were
allowed to grow for 9 days and reached approximately 8–10mm
diameter. On day 9, control mice received PBS; experimental mice
received a single dose of Cy 100mgkg
 1 i.p. After 2 days, pH
measurements were obtained.
C57Bl6 mice (n¼16 each group) were inoculated sub-
cutaneously in the flank with 0.1 million ADR-sensitive or
ADR-resistant B16-BL6 cells. On day 6 after tumour inoculation,
control mice started receiving PBS and experimental mice received
doxorubicin, 2mgkg
 1 i.p. daily. Treatment was continued for a
total of 6 days, followed by tumour pH measurements.
Single pH measurements An Orion 98–63 micro-pH electrode
(Thermo Electron Corp., Beverly, MA, USA), a 16-gauge bevelled
tip electrode (1.6mm OD) coupled to an Orion 310 PerpHecT pH
meter (Thermo Electron Corp.), was used to measure intra-
tumoural pH. The electrode was autocalibrated with pH 4.00 and
7.00 buffers (Corning, Woburn, MA, USA) before each series of
measurements. Mice were anaesthetised with ketamine/xylazine/
acepromazine (50/5/1mgkg
 1 i.p.) before pH measurement. The
bevelled pH probe was inserted transcutaneously into the tumours.
Measurements were taken in the central region of the tumours as
well as in the tumour-free s.c. region of the posterior cervical
midline. Each experiment was performed three times with similar
results. Student’s t-test (two-tailed homoscedastic) was utilised to
determine P-values and statistical significance between groups.
Kinetics of intra-tumoural pH C57Bl6 mice (n¼6 each group)
were inoculated subcutaneously in the mid-dorsal lumbar region
with 0.1 million ADR-sensitive or ADR-resistant B16-BL6 cells. On
day 4 after tumour inoculation, 2-mm-diameter tubes with ion-
selective polyvinyl chloride membranes covering the distal end
(Kwik-Tip-H; World Precision Instruments, Sarasota, FL, USA)
were introduced through an incision in the dorsal thoracic region,
tunnelled through the dorsal s.c. space, and the distal tip placed in
the centre of the tumour. The incision was closed and the tube was
fixed in place with 5-0 Vicryl suture; thus, tubes remained in situ
for the duration of the study. On day 6, control mice started
receiving PBS and experimental mice received doxorubicin,
2mgkg
 1 i.p. daily, continued for a total of 6 days. Following
administration of general anaesthesia as above, tumour pH was
assessed on day 6 (5min pre- and 5min post-doxorubicin), and on
days 7, 10, 13, and 16 by introduction of the calibrated Kwik-Tip-H
electrode into the implanted tube containing 1 M citric acid and
0.01 M NaCl (pH 5.6). The 2mm polyvinyl chloride-coated
reference electrode (SDR2; World Precision Instruments) was
introduced through a separate 2mm incision in the flank. It was
recognised that, if this preclinical approach were successful, a
modified system of measurement would be required for routine
clinical application, and design of such a system is in progress.
Animal welfare All murine studies were conducted under
compliance with the Cleveland Clinic Institutional Animal Care
and Use Committee, under Animal Welfare Assurance A3047-01.
RESULTS
P388 murine leukaemia is exquisitely sensitive to the cytotoxic
effects of Cy. To determine whether tumour regression was
associated with changes in tumour pH, we treated mice bearing
established s.c. syngeneic tumours with a single dose of Cy or PBS.
Tumours in both treatment groups were acidotic at baseline,
compared to normal s.c. tissue (Figure 1). The lowest tumour mean
pH was observed following Cy treatment compared to PBS
(5.6±0.2 and 6.3±0.2, respectively, P¼0.001). There was no
difference in the pH measured in the s.c. tissue in the cervical
region in Cy- and PBS-treated mice (7.3 for both, P¼0.97).
Tumours grew progressively in the PBS group, whereas tumours
underwent regression in the Cy group (Figure 2). Cyclophos-
phamide treatment resulted in 80% complete remission and long-
term survival (90 days), whereas there were no survivors in the
PBS-treated group (Figure 3). Hence, long-term survival was
predicted by induction of acidosis within tumours.
To determine if this phenomenon was cell type specific, we
selected a murine melanoma model consisting of drug-resistant
and drug-sensitive sublines. We have previously used this model
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sextensively for other unrelated studies of cytotoxicity and clonality
of response (Ganapathi et al, 1988). We recognised that the drug
responsive sublines of a melanoma xenograft do not necessarily
translate to responsiveness in the clinical setting, but simply used
this line as a comparative model of cytotoxic response and
resistance for the purposes of illustrating this general pheno-
menon. Antiproliferative assays were conducted to determine the
in vitro ADRIC50 values for both B16-BL6 sublines. Adriamycin-
resistant cells were not growth inhibited by 0.01–0.25mgml
 1
ADR, whereas the ADRIC50 for ADR-sensitive cells was approxi-
mately 0.15mgml
 1 (Figure 4). Hence, the ADR-resistant cells
proved to be resistant in vitro.
The B16-BL6 sublines were established as s.c. tumours in C57Bl6
mice, followed by a 6-day course of either PBS or ADR. Following
ADR treatment, ADR-sensitive tumours displayed a lower intra-
tumoural pH compared to resistant tumours (5.4±0.1 and
6.4±0.2, respectively, P¼3.5 10
 7) (Figure 5). There was no
significant difference in cervical s.c. pH (representing normal,
non-malignant tissues at a close but not contiguous site) between
ADR-sensitive or ADR-resistant tumour-bearing mice, whether
they were treated with ADR or PBS (data not shown). By 12 days
following the last treatment, all mice bearing ADR-resistant
tumours had died (or were terminated because of excessive
tumour size), as had mice bearing ADR-sensitive tumours treated
with PBS (Figure 6A). However, mice with ADR-sensitive tumours
that had received ADR displayed 100% survival. Kinetic studies
indicated that the maximal drop in pH occurred 24h post-
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Figure 2 P388 tumour volume in DBA/2 mice. Mice bearing established
s.c. P388 tumours received 100mgkg
 1 Cy on day 0. Intra-tumoural pH
was assessed on day 2 (indicated by arrow), as above.
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Figure 3 Survival of mice bearing P388 tumours. Mice from Figure 2
were monitored for survival following single-dose of Cy or vehicle.
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Figure 4 Antiproliferative effects of doxorubicin (ADR) against B16-BL6
murine melanoma. Doxorubicin sensitive (Sen) and resistant (Res) sublines
of B16-BL6 were treated with doxorubicin in vitro and growth was assessed
after 4 days. Negative values on the y-axis indicate death of initially plated
cells (n¼8 each dose).
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Figure 1 Measurement of extra-cellular pH in P388 murine monocytic
leukaemia tumours and normal tissues in DBA/2 mice. Extra-cellular pH
measurements of established (11-day-old) subcutaneous tumours and the
subcutaneous tissues of the posterior neck were obtained using a micro-
electrode. Mice had received PBS or cyclophosphamide (Cy) 2 days
previously (n¼24 each group).
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Figure 5 Measurement of intra-tumoural pH in B16-BL6 tumours. Extra-
cellular pH measurements of sensitive and resistant B16-BL6 tumours were
obtained following doxorubicin (ADR, 2mgkg
 1 6 days) or PBS
treatment. SP (sensitive, PBS), RP (resistant, PBS), SA (sensitive, ADR),
RA (resistant, ADR) designations indicate cell subline and treatment
(n¼16 mice each group).
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(Figure 6B). Hence, induction of tumour acidosis again translated
into a positive therapeutic response.
DISCUSSION
In this preclinical study, we have demonstrated clearly that intra-
tumoural, extra-cellular pH changes dramatically in response to
two different chemotherapy regimens in responsive tumours. In
contrast, chemotherapy-resistant tumours are not associated with
this change in pH, and control tumour-bearing mice treated with
saline show no pH changes. Not surprisingly, long-term survival
has correlated directly with the extent of pH change, reflecting the
extent of initial tumour cell kill. This model suggests that early
intra-tumour measurement of pH change in the clinical setting
may predict outcome of chemotherapy, and thus may provide a
useful tool to allow earlier prediction in clinical practice.
It is possible that the local changes in acidity are not merely a
reflection of cell kill, but may be part of the process. It has been
shown that tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a potential anticancer agent that induces a
greater level of necrosis-like cell death under acidic conditions
than at physiological pH (Meurette et al, 2007), and this may
reflect induction of caspase function (Lee et al, 2004; Meurette
et al, 2005). A range of other proteases are induced at acidic pH,
and while one usually thinks of these in association with
mechanisms of invasion and metastasis, it is possible that they
also contribute to local tumour destruction once a cascade of cell
necrosis has been initiated. Our future preclinical studies will focus
on the interactions of expression of TRAIL, a series of proteases
and the balance of apoptosis and necrosis in response to cytotoxic
chemotherapy.
However, at present our data strongly support the concept that
measurement of extra-cellular pH changes will allow clinical
prediction of response to chemotherapy, and we are initiating a
clinical trial to test this hypothesis, using single needle probe
measurement of pH at set time points after initial cytotoxic
chemotherapy.
The obvious problem with this approach is the innate, potential
discomfort for patients, notwithstanding the use of a scaled-down
probe size that we are developing. Furthermore, this measurement
technology would only be applicable to easily accessed tumour
deposits, such as cutaneous metastases, localised breast cancers,
and lymph node masses. However, another potential tool that
could exploit the same underlying pathophysiology would be the
use of non-invasive magnetic resonance spectroscopy to measure
similar end points, and this could much more easily be applied to
visceral tumour deposits. This also will be the subject of future
studies.
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